118 related articles for article (PubMed ID: 29336967)
1. Con: Activated Clotting Time Should Not Be Monitored During Heparinization for Vascular Surgery.
Wolo E; Herman C
J Cardiothorac Vasc Anesth; 2018 Jun; 32(3):1497-1499. PubMed ID: 29336967
[No Abstract] [Full Text] [Related]
2. Con: The Hepcon HMS Should Not Be Used Instead of Traditional Activated Clotting Time to Dose Heparin and Protamine for Cardiac Surgery Requiring Cardiopulmonary Bypass.
Gilly G; Trusheim J
J Cardiothorac Vasc Anesth; 2016 Dec; 30(6):1730-1732. PubMed ID: 27751763
[No Abstract] [Full Text] [Related]
3. Pro: The Hepcon HMS Should Be Used Instead of Traditional Activated Clotting Time (ACT) to Dose Heparin and Protamine for Cardiac Surgery Requiring Cardiopulmonary Bypass.
Ural K; Owen C
J Cardiothorac Vasc Anesth; 2016 Dec; 30(6):1727-1729. PubMed ID: 27641953
[No Abstract] [Full Text] [Related]
4. Prolonged Activated Clotting Time after Protamine Administration Does Not Indicate Residual Heparinization after Cardiopulmonary Bypass in Pediatric Open Heart Surgery.
Yamamoto T; Wolf HG; Sinzobahamvya N; Asfour B; Hraska V; Schindler E
Thorac Cardiovasc Surg; 2015 Aug; 63(5):397-403. PubMed ID: 26121380
[TBL] [Abstract][Full Text] [Related]
5. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass.
Akl BF; Vargas GM; Neal J; Robillard J; Kelly P
J Thorac Cardiovasc Surg; 1980 Jan; 79(1):97-102. PubMed ID: 7350393
[TBL] [Abstract][Full Text] [Related]
7. Activated clotting time for control of anticoagulation during surgery.
Lefemine AA; Lewis M
Am Surg; 1985 May; 51(5):274-8. PubMed ID: 3994170
[TBL] [Abstract][Full Text] [Related]
8. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.
Mochizuki T; Olson PJ; Szlam F; Ramsay JG; Levy JH
Anesth Analg; 1998 Oct; 87(4):781-5. PubMed ID: 9768770
[TBL] [Abstract][Full Text] [Related]
9. Low activated coagulation time during cardiopulmonary bypass does not increase postoperative bleeding.
Metz S; Keats AS
Ann Thorac Surg; 1990 Mar; 49(3):440-4. PubMed ID: 2310251
[TBL] [Abstract][Full Text] [Related]
10. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.
Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
J Thorac Cardiovasc Surg; 1983 Feb; 85(2):174-85. PubMed ID: 6823136
[TBL] [Abstract][Full Text] [Related]
11. Heparin monitoring during cardiopulmonary bypass.
Saleem A; Shenaq SS; Yawn DH; Harshberger K; Diemunsch P; Mohindra P
Ann Clin Lab Sci; 1984; 14(6):474-9. PubMed ID: 6508227
[TBL] [Abstract][Full Text] [Related]
12. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery.
Vonk AB; Veerhoek D; van den Brom CE; van Barneveld LJ; Boer C
J Cardiothorac Vasc Anesth; 2014 Apr; 28(2):235-41. PubMed ID: 24342152
[TBL] [Abstract][Full Text] [Related]
13. Activated clotting time monitoring of intraoperative heparinization: our experience and comparison of two techniques.
Mabry CD; Thompson BW; Read RC; Campbell GS
Surgery; 1981 Nov; 90(5):889-95. PubMed ID: 7302842
[TBL] [Abstract][Full Text] [Related]
14. Pro: Activated Clotting Time Should Be Monitored During Heparinization For Vascular Surgery.
Goldhammer JE; Zimmerman D
J Cardiothorac Vasc Anesth; 2018 Jun; 32(3):1494-1496. PubMed ID: 28943189
[No Abstract] [Full Text] [Related]
15. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
[TBL] [Abstract][Full Text] [Related]
16. Use of activated clotting time to monitor anticoagulation during cardiac surgery.
Niinikoski J; Laato M; Laaksonen V; Jalonen J; Inberg MV
Scand J Thorac Cardiovasc Surg; 1984; 18(1):57-61. PubMed ID: 6609429
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery.
Babka R; Colby C; El-Etr A; Pifarré R
J Thorac Cardiovasc Surg; 1977 May; 73(5):780-2. PubMed ID: 850438
[TBL] [Abstract][Full Text] [Related]
18. Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgery.
Najman DM; Walenga JM; Fareed J; Pifarré R
Ann Thorac Surg; 1993 Mar; 55(3):662-6. PubMed ID: 7680854
[TBL] [Abstract][Full Text] [Related]
19. Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis.
Verska JJ
Ann Thorac Surg; 1977 Aug; 24(2):170-3. PubMed ID: 879898
[TBL] [Abstract][Full Text] [Related]
20. Activated clotting time (ACT) monitoring of intraoperative heparinization in peripheral vascular surgery.
Mabry CD; Thompson BW; Read RC
Am J Surg; 1979 Dec; 138(6):894-900. PubMed ID: 507308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
